We help emerging biotechs expand into Europe, the Middle East & Eurasia while minimizing risk and accelerating patient access.
Due to many barriers, Expanding Rare Disease Drugs across EMEE remains a challenge despite it represents over 40% of Global sales.
Only 260 drugs with orphan drug status are approved in the EU, while +/- 880 are approved in the USA.
Despite the EMEE region accounting for more than 40% of global rare disease drug sales, emerging biotechs struggle to expand due to high upfront investment, regulatory complexity, market fragmentation, and access barriers.
The Next Decade: An expected +150% Surge in the Global Orphan Drug Market and Growth in Cell & Gene Therapies create an opportunistic environment for rare disease companies. The Rare Disease Market is estimated to be at $266.3bn in 2034 for Europe.
We combine strategic go-to-market advisory with a fully licensed ready commercial platform. Our phased model de-risksentry, accelerates patient access, and ensures you retain control of your product and strategy.
Huge investment in setting up own footprint with high risks* & longer lead time
Multiple healthcare systems, reimbursement processes and supply chain challenges
Complex regulatory pathways some markets carry greater exposure to compliance risks
Limited portfolio of commercial assets reducing ROI & revenue opportunity
Exiting routes: Go-Alone, Distributors or out-licencing
The problem is severe as limited funds and high costs deter biotechs from expanding to EMEE, denying patients access to vital products, and causing revenue loss.